Silexion Therapeutics Corp (NASDAQ:SLXN) Short Interest Update

Silexion Therapeutics Corp (NASDAQ:SLXN) saw a large increase in short interest in the month of September. As of September 15th, there was short interest totaling 238,617 shares, an increase of 1,545.5% from the August 31st total of 14,501 shares. Based on an average daily trading volume, of 15,566,949 shares, the days-to-cover ratio is currently 0.0 days. Approximately 4.3% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Several analysts have commented on SLXN shares. Maxim Group cut shares of Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Friday, September 11th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold”.

Silexion Therapeutics Stock Performance

Shares of SLXN stock traded down $0.06 on Thursday, hitting $0.26. The company had a trading volume of 2,303,255 shares, compared to its average volume of 12,627,722. The company has a 50-day moving average price of $0.98 and a 200-day moving average price of $5.13. Silexion Therapeutics has a twelve month low of $0.25 and a twelve month high of $42.60.

Silexion Therapeutics (NASDAQ:SLXN) last posted its earnings results on Saturday, August 15th. The company reported ($5.17) EPS for the quarter, topping the consensus estimate of ($21.20) by $16.03. On average, equities analysts expect that Silexion Therapeutics will post -4.7 EPS for the current year.

About Silexion Therapeutics

Silexion Therapeutics Ltd. is an Israel-based clinical-stage biotechnology company focused on developing RNA-based treatments for solid tumors driven by mutations in the KRAS gene. The company’s research is centered on gene-silencing technologies designed to inhibit KRAS, an important cancer-promoting protein that has historically been difficult to target with conventional therapies.

Silexion’s development programs include SIL-204, an investigational small interfering RNA (siRNA) therapy designed to target KRAS mutations, including KRAS G12D, a frequently observed mutation in pancreatic cancer.